Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men ...

ADMA Biologics’ ADMA shares have lost 8.9% in a month against the industry’s growth of 6.6%. The company has put up a ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of ...

South Dakota’s HB 1109 would mirror a new Florida law, prohibiting the manufacture, sale, or distribution of cell-cultured meat. An amendment added to the bill sunsets the rule in 10 years. Arizona, ...

AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.